← Back to headlines
RBC Capital Lifts Price Target for Incyte Corporation
RBC Capital has raised its price target for Incyte Corporation (INCY) from $92 to $95. This upward adjustment reflects a more positive financial outlook for the biopharmaceutical company.
20 Apr, 00:08 — 20 Apr, 00:08
Sources
Showing 1 of 1 sources
Related Stories
Lionel Richie Hospitalized in ICU Following St. Louis Concert
3h ago
Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue
10h ago
Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases
13h ago
England Pharmacies to Offer Free Quick Cholesterol Screening Tests
21h ago